Real World Experience of Long Term Treatment Outcome in Hormone Receptor-positive Metastatic Breast Cancer with or without Everolimus and Exemestane after Prior Aromatase Inhibitor
Background: Everolimus/exemestane has been shown to improve progression-free survival in patients with endocrine-resistant metastatic breast cancer. The regimen has been well-accepted despite lack of survival benefit. In real-life setting, patients were not well-selected and hence benefit of such tr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
West Asia Organization for Cancer Prevention
2021-05-01
|
| Series: | Asian Pacific Journal of Cancer Care |
| Subjects: | |
| Online Access: | http://www.waocp.com/journal/index.php/apjcc/article/view/603 |